WO2023067388 - USES OF CFTR MODULATOR AND/OR PDE4 INHIBITOR COMPOUNDS
National phase entry is expected:
Publication Number
WO/2023/067388
Publication Date
27.04.2023
International Application No.
PCT/IB2022/000612
International Filing Date
21.10.2022
Title **
[English]
USES OF CFTR MODULATOR AND/OR PDE4 INHIBITOR COMPOUNDS
[French]
UTILISATIONS DE COMPOSÉS MODULATEURS DE CFTR ET/OU INHIBITEURS DE PDE4
Applicants **
ILDONG PHARMACEUTICAL CO., LTD.
2, Baumoe-ro 27-gil
Seocho-gu
Seoul
06752, KR
Inventors
KIM, Kyeong-A
2 Baumoe-ro 27-gil
Seocho-gu
Seoul 06752, KR
OH, Changmok
2 Baumoe-ro 27-gil
Seocho-gu
Seoul 06752, KR
LEE, Seolhee
2 Baumoe-ro 27-gil
Seocho-gu
Seoul 06752, KR
LIM, Dami
2 Baumoe-ro 27-gil
Seocho-gu
Seoul 06752, KR
JEONG, Ilji
2 Baumoe-ro 27-gil
Seocho-gu
Seoul 06752, KR
YOON, Hongchul
2 Baumoe-ro 27-gil
Seocho-gu
Seoul 06752, KR
PARK, Joontae
2 Baumoe-ro 27-gil
Seocho-gu
Seoul 06752, KR
AN, Kyung Mi
2 Baumoe-ro 27-gil
Seocho-gu
Seoul 06752, KR
LEE, Jung Woo
2 Baumoe-ro 27-gil
Seocho-gu
Seoul 06752, KR
Priority Data
63/270,741
22.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
MOIP
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3461 | |
| EPO | Filing, Examination | 12959 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 5560 |
Total: 23149 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides methods of using CFTR modulator compounds and compositions including said compounds for modulating CFTR, methods for treating an eye disease or disorder, and methods for treating CFTR-related indications. The present disclosure also provides methods of using PDE4 inhibiting compounds and compositions including said compounds for inhibiting PDE4. In some embodiments, the PDE4 inhibitor compounds of this disclosure are anti-inflammatory compounds capable of activation of target CFTR. The present disclosure also provides methods of using said compounds and compositions for treating an inflammatory disease or disorder, and methods for treating PDE4-related indications.[French]
La présente invention concerne des procédés d'utilisation de composés modulateurs de CFTR et des compositions comprenant lesdits composés pour la modulation de CFTR, des procédés de traitement d'une maladie ou d'un trouble oculaire, et des procédés de traitement d'indications liées au CFTR. La présente invention concerne également des procédés d'utilisation de composés inhibiteurs de PDE4 et des compositions comprenant lesdits composés pour inhiber PDE4. Dans certains modes de réalisation, les composés inhibiteurs de PDE4 de la présente invention sont des composés anti-inflammatoires capables d'activer le CFTR cible. La présente invention concerne également des procédés d'utilisation desdits composés et compositions pour le traitement d'une maladie ou d'un trouble inflammatoire, et des procédés de traitement d'indications liées à PDE4.